AbbVie to buy Aliada Therapeutics for $1.4B in cash
Contributor since / Followers
vzphotos/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B in cash.
The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.
The deal enables AbbVie (ABBV) to leverage Aliada’s novel blood-brain barrier-crossing technology to enhance discovery and development efforts across neuroscience.
Aliada’s lead drug candidate, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer’s disease. The company is also pursuing programs in other neurological disorders.
“This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer’s disease. In addition, Aliada’s novel BBB-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders and other diseases where enhanced delivery of therapeutics into the CNS is beneficial,” said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie (ABBV).